跳到正文
原文
The Lancet· Domenica Lorusso, Jérôme Martin-Babau, Floor Backes, Maria Pilar Barretina Ginesta, Jacob Korach, Shibani Nicum, Julian Wampfler, Jianqing Zhu, Monika Ducceschi, Toon Van Gorp, Magnus Frödin-Bolling, Flora Zagouri, Judith R Kroep, Isabelle Ray-Coquard, Vanda Salutari, Michelle D S Lightfoot, Todd Tillmanns, David M O’Malley, Kosei Hasegawa, Jung-Yun Lee, Gonzalo H Giornelli, Vanessa Samouëlian, Yoland Antill, Jundong Li, Shin Nishio, Jack Junjie Chan, Bradley J Monk, Chenxiang Li, Kristina Woodhouse, Robert Orlowski, Carmen García-Duran, Bhavana Pothuri, TroFuse-005/ENGOT-en23/GOG-3095 Investigators·· 24 天前精选AI 评分82

Sac-TMT对比医生选择方案治疗经治子宫内膜癌的III期试验结果发表

[Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial

AI 导读

TroFuse-005/ENGOT-en23/GOG-3095 III期试验显示,sacituzumab tirumotecan(Sac-TMT)在既往接受铂类化疗和免疫治疗的晚期或复发性子宫内膜癌患者中,较医生选择方案(TPC)显著改善无进展生存期和总生存期。研究结果支持Sac-TMT成为已接受化疗和免疫治疗、有效治疗选择有限患者的新标准治疗。

推荐理由

III期试验显示该ADC在经治晚期子宫内膜癌中同时改善PFS与OS,读者可据此判断其成为新治疗选择的依据。

来源:The Lancet · thelancet.com